From bench to bedside [electronic resource] : evolution of anti-TNFα therapy in rheumatoid arthritis / Ravinder Maini.

By: Material type: FilmFilmPublisher number: 2179 | Henry Stewart TalksSeries: Henry Stewart talks. Biomedical & life sciences collection. Innate immunity : host recognition and response in health and disease.Publication details: London : Henry Stewart Talks, 2009.Description: 1 online resource (1 streaming video file (59 min.) : color, sound)Subject(s): Online resources:
Contents:
Contents: What are cytokines? -- Early experiments -- Human cytokines in the 1980s -- Identification of TNFalfa at protein and genomic level -- TNFalfa and anti- TNFalfa antibodies -- Rheumatoid arthritis (RA): burden of disease -- Pathology of RA -- IL-1 and TNFalfa -- Cytokine cascade in RA -- A molecular hypothesis -- First anti-TNF (cA2/infliximab) in clinical trials in RA -- How does anti-TNF work? -- Why is cellularity reduced? -- Anti-TNF therapy inhibits cartilage and especially bone destruction -- Infliximab regulates altered T and B cell immunity -- Biological effects of Infliximab -- Anti-TNF biologicals in the lab -- Efficacy in randomized clinical trials -- Effective anti-TNF therapy demonstrates shared TNF-pathways in other diseases -- Adverse events and safety issues -- Limitations of anti-TNF therapy -- After TNF: what are we looking for?
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Animated audio-visual presentation with synchronized narration.

Title from title frames.

Contents: What are cytokines? -- Early experiments -- Human cytokines in the 1980s -- Identification of TNFalfa at protein and genomic level -- TNFalfa and anti- TNFalfa antibodies -- Rheumatoid arthritis (RA): burden of disease -- Pathology of RA -- IL-1 and TNFalfa -- Cytokine cascade in RA -- A molecular hypothesis -- First anti-TNF (cA2/infliximab) in clinical trials in RA -- How does anti-TNF work? -- Why is cellularity reduced? -- Anti-TNF therapy inhibits cartilage and especially bone destruction -- Infliximab regulates altered T and B cell immunity -- Biological effects of Infliximab -- Anti-TNF biologicals in the lab -- Efficacy in randomized clinical trials -- Effective anti-TNF therapy demonstrates shared TNF-pathways in other diseases -- Adverse events and safety issues -- Limitations of anti-TNF therapy -- After TNF: what are we looking for?

Access restricted to subscribers.

Mode of access: World Wide Web.

There are no comments on this title.

to post a comment.